智通财经网·2025-11-07 01:28Core Viewpoint - BeiGene reported strong financial results for Q3 2025, with significant revenue and profit growth driven by the sales of its product, Brukinsa, in the US and Europe [1][2] Financial Performance - For Q3 2025, BeiGene's revenue reached $1.412 billion, a year-on-year increase of 41% [1] - Adjusted net profit for Q3 was approximately $304 million, reflecting a substantial year-on-year growth of 489% [1] - GAAP net profit was $125 million, marking a return to profitability compared to the previous year [1] - Total revenue for the first nine months of 2025 was approximately $3.845 billion, up 43% year-on-year [1] - Adjusted net profit for the same period was about $693 million, also indicating a return to profitability [1] - GAAP net profit for the first nine months was approximately $220 million, showing a turnaround from losses [1] Revenue Drivers - The revenue growth was primarily attributed to the increase in sales of Brukinsa in the US and Europe [1] - Product revenue for Q3 was $1.4 billion, compared to $993 million in the same period last year [1] - The US remains the largest market for the company, with product revenue of $743 million, up from $504 million year-on-year [1] - Sales from licensed products obtained from Amgen and the sales of Tislelizumab also contributed to the revenue growth [1] Future Guidance - BeiGene's total revenue guidance for the full year 2025 is set between $5.1 billion and $5.3 billion, reflecting strong growth expectations [2] - The company anticipates that gross margin will be in the mid-to-high range of 80% to 90% due to improved product mix and production efficiency compared to 2024 [2]